Clinical Evaluation Costs: Why Most Budgets Collapse Midway

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Budget planning for clinical evaluation is not a financial exercise. It is a regulatory risk assessment translated into resources. Most manufacturers treat it as a one-time estimate at project start. Then reality hits.

The clinical evaluation process under MDR is iterative, document-heavy, and review-intensive. It requires clinical expertise, literature surveillance, appraisal methodology, equivalence justification, PMCF planning, and multiple rounds of refinement based on Notified Body feedback. Each of these elements has a cost. And each cost depends on decisions you make early in the process.

If you underestimate, you either stop midway or compromise quality. If you overestimate without structure, you waste resources on activities that add no regulatory value. Both outcomes are common.

The question is not whether clinical evaluation is expensive. The question is: what drives the cost, and how do you plan for it without gambling?

What Drives Clinical Evaluation Cost

Clinical evaluation cost is not fixed. It depends on your device, your claims, your predicate strategy, and your data landscape. But the cost drivers are predictable.

The first driver is the scope of the literature search. A Class IIa device with a well-established technology and decades of published data requires a different search strategy than a Class III implant with novel features. Search scope determines not only database fees but also the time required for screening, selection, and appraisal. A search that returns 8,000 citations requires more hours to filter than one that returns 800. This is linear effort.

The second driver is appraisal depth. Under MDR Article 61 and Annex XIV, every study included in your clinical evaluation must be appraised for relevance and methodological quality. This is not a checkbox. It requires clinical judgment, understanding of study design, and ability to identify bias or confounders. Appraisal is what separates a compliant CER from a deficient one. It also takes time.

The third driver is equivalence demonstration. If you claim equivalence to another device under MDCG 2020-5, you must justify technical, biological, and clinical equivalence with objective evidence. This often requires gap analysis, additional testing, and clinical data comparison. Equivalence work can double the resource requirement if the predicate device was chosen without full analysis upfront.

The fourth driver is clinical data generation. If literature and equivalence are insufficient, you need clinical investigations or PMCF. These are not CER costs, but they delay the CER finalization and create iterative review cycles. Budget planning must account for the possibility that data gaps emerge during appraisal.

The fifth driver is Notified Body interaction. Every submission triggers questions. Every question requires time to respond, documents to update, and sometimes additional searches or analyses. This is not rework. It is part of the conformity assessment process. But most budgets do not account for it.

How Budget Estimates Go Wrong

Most budget estimates collapse because they are based on assumptions that sound reasonable but do not reflect how clinical evaluation work actually unfolds.

The first mistake is treating the CER as a one-time deliverable. Manufacturers budget for a single report. But the CER is a living document under MDR Article 61(11). It must be updated with new data, new literature, and new PMCF findings. Initial CER preparation is just the start. Update cycles must be budgeted separately.

The second mistake is underestimating appraisal effort. I see budgets that allocate two hours per study for appraisal. For a simple case series, maybe. For a randomized controlled trial with 200 pages of supplementary data, no. Appraisal time depends on study complexity, not just study count.

The third mistake is ignoring internal review cycles. Clinical evaluation is cross-functional. It requires input from R&D, regulatory, clinical affairs, and sometimes quality and post-market surveillance. Each review cycle adds time. Each revision adds cost. If you budget only for the consultant or the clinical evaluator, you miss half the effort.

The fourth mistake is not planning for scope changes. A device classification shifts. A claim is refined. A competitor launches a similar device with new data. Regulatory expectations evolve. These changes force CER revisions. If the budget has no contingency, the project stalls.

Building a Realistic Budget Structure

A structured budget starts with scope definition. Before you estimate cost, you must define what the clinical evaluation will cover. This means answering specific questions.

What is the intended purpose? What are the clinical claims? What are the clinical benefits and residual risks? What is the state of the art? Is equivalence claimed? If yes, to which device and based on what data? What literature exists? What clinical data do you already have? What data gaps are anticipated?

These questions define scope. Scope defines effort. Effort defines cost.

Once scope is clear, break the clinical evaluation into phases. The typical structure includes:

Phase 1: Literature search and screening. This includes search strategy development, database queries, citation screening, and full-text retrieval. Budget by estimated citation volume and screening time per citation. Expect 30 to 90 seconds per title-abstract screening and 10 to 30 minutes per full-text review depending on complexity.

Phase 2: Appraisal and data extraction. This includes relevance assessment, methodological quality appraisal using structured tools, and data extraction into appraisal tables. Budget by number of included studies and study type. A case series takes less time than a multi-arm RCT with subgroup analyses.

Phase 3: Equivalence demonstration (if applicable). This includes technical characterization, biological safety comparison, clinical data comparison, and gap analysis. Budget depends on predicate complexity and data availability. If predicate data is sparse, equivalence work expands significantly.

Phase 4: CER drafting and internal review. This includes synthesis of appraisal findings, benefit-risk evaluation, SOTA comparison, risk mitigation analysis, and PMCF planning. Budget for multiple internal review cycles and revisions.

Phase 5: Notified Body submission and response. Budget for question response, document updates, and potential re-submission cycles. Plan for at least two question rounds and one major revision cycle.

Phase 6: CER updates and PMCF integration. Budget annually for literature surveillance, new data integration, and CER updates per MDR Article 61(11).

What Class and Risk Profile Mean for Budget

Device class and risk profile directly influence clinical evaluation complexity and therefore cost. This is not about Notified Body fees. It is about the depth and breadth of evidence required.

Class I devices with established equivalents and minimal claims require focused clinical evaluations. Literature searches are targeted. Appraisal volume is manageable. Equivalence is often straightforward. Budget expectations for a Class I device CER typically range from basic to moderate depending on data availability.

Class IIa and IIb devices require more robust evaluations. Claims are broader. Risks are higher. Equivalence must be demonstrated with more rigor per MDCG 2020-5. Literature volume increases. Appraisal depth increases. PMCF planning becomes mandatory and more detailed. Budgets scale accordingly.

Class III and implantable devices require the highest level of scrutiny. Clinical investigations are often necessary. Equivalence claims are heavily questioned. Literature appraisal must cover long-term safety and performance. PMCF must include registries or systematic follow-up. These requirements multiply resource needs. A Class III CER can require three to five times the effort of a Class IIa CER for similar technology.

Beyond class, consider whether your device introduces novel features, new materials, new patient populations, or new clinical indications. Each of these expands the scope of literature review, increases appraisal complexity, and raises Notified Body expectations. Budget must reflect this.

Hidden Costs That Break Timelines

Some costs are not obvious until the project is underway. These are the hidden costs that break timelines and force budget overruns.

The first is access to full-text articles. Most literature searches identify relevant citations, but retrieving full-text papers costs money. Journal subscriptions, pay-per-article fees, and interlibrary loans add up quickly when you need 50 to 200 papers. Budget for this separately.

The second is translation services. If key studies are published in languages other than English, you need professional translation. Machine translation is not acceptable for regulatory submissions. Translation costs vary by language and document length but can be significant if multiple papers require translation.

The third is database access fees. Comprehensive literature searches require access to multiple databases beyond PubMed. EMBASE, Cochrane Library, and device-specific registries often require paid subscriptions or per-search fees. If your organization does not have these subscriptions, factor them into the budget.

The fourth is external expert review. For high-risk devices or novel technologies, Notified Bodies may expect input from independent clinical experts. External expert review is not always required, but when it is, it adds both cost and timeline.

The fifth is internal resource time. Clinical evaluation is not outsourced entirely. Your team must review drafts, provide device-specific input, coordinate with R&D, and respond to Notified Body questions. This internal time has a cost even if it is not billed separately. Many budgets ignore it.

When to Budget for Clinical Investigations

If literature and equivalence cannot support your claims, clinical investigations are needed. This is not a CER budget item, but it affects CER timing and cost because the CER cannot be finalized until clinical data is available.

Clinical investigations require separate budgets that include protocol development, ethics approval, site contracts, patient enrollment, monitoring, data management, statistical analysis, and reporting. Costs depend on study design, patient population, number of sites, and follow-up duration.

But here is what affects the CER budget: the CER must integrate clinical investigation results. This means additional appraisal work, data synthesis, and report updates after the investigation concludes. Budget for this integration phase separately.

Also budget for PMCF integration. PMCF is mandatory under MDR Article 61(11) and Annex XIV Part B. PMCF data must be systematically collected, analyzed, and integrated into CER updates. This is an ongoing cost, not a one-time cost. Annual PMCF review and CER updates must be part of long-term budget planning.

How to Build Contingency Without Waste

Contingency is not padding. It is planned flexibility for known unknowns. The difference is structure.

Identify the variables that could expand scope. These include: higher-than-expected citation volume in literature search, discovery of new predicate device data requiring equivalence re-analysis, Notified Body requests for additional clinical data or extended appraisal, changes to device claims or indications during development, and new safety signals requiring risk re-evaluation.

For each variable, estimate the probability and the potential cost impact. Allocate contingency proportionally. For example, if there is a 50 percent chance that Notified Body questions will require one additional appraisal cycle, budget 50 percent of one cycle cost as contingency.

Track contingency usage. If scope changes occur, document the reason, the added effort, and the cost impact. This creates a knowledge base for future projects and improves estimation accuracy over time.

What Happens When Budget Runs Out

When budget runs out mid-project, manufacturers face three choices: stop work and delay submission, continue with reduced scope and risk deficiencies, or request additional budget and explain the overrun.

Stopping work delays market access. Every month of delay has an opportunity cost. For some devices, that cost exceeds the clinical evaluation budget. But stopping is sometimes the right choice if continuing with insufficient resources leads to a deficient CER that fails Notified Body review.

Reducing scope is the worst choice. It leads to incomplete appraisals, weak equivalence justifications, or missing SOTA analysis. These deficiencies are flagged immediately during Notified Body review. The result is major non-conformities, re-submission, and longer delays than if the work had been paused and properly funded.

Requesting additional budget is the most common path, but it requires justification. This is where structured budget planning pays off. If you can show that scope expanded due to Notified Body requirements, new data availability, or device changes, the request is defensible. If the overrun is due to poor initial estimation, it is harder to justify.

The lesson: budget accuracy depends on upfront planning. Spend time on scope definition and risk assessment before committing to cost estimates. An extra week of planning can prevent months of budget crisis.

Long-Term Cost Planning for CER Updates

The CER is not a one-time deliverable. MDR Article 61(11) requires updates throughout the device lifecycle. This means annual literature surveillance, PMCF data integration, and periodic CER revisions.

Budget for annual updates separately from initial CER development. Update costs are lower than initial development but still significant. Typical activities include: new literature search covering the past year, appraisal of new studies, integration of PMCF findings, revision of benefit-risk evaluation, and update of PMCF plan based on new data.

Updates are not optional. They are part of post-market clinical follow-up obligations under Annex XIV Part B. Failure to update the CER is a non-conformity. Budget for this work annually as part of post-market surveillance costs.

Also plan for major CER revisions triggered by significant device changes, new clinical indications, safety signals, or changes in state of the art. Major revisions require more effort than annual updates and should be budgeted as separate projects.

Final Thought

Budget planning for clinical evaluation is not about predicting the future. It is about understanding the work, identifying the variables, and allocating resources with enough structure to absorb uncertainty without collapsing.

The manufacturers who stay on budget are not the ones who estimate perfectly. They are the ones who plan for contingency, track scope changes, and adjust early when reality diverges from plan.

Clinical evaluation cost is not a fixed number. It is a function of decisions you make about device claims, equivalence strategy, literature depth, and risk management. Control those decisions, and you control the cost.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.